We know that there's going to be a favorable presentation on baricitinib next month. We know that management will give a professional-sounding presentation at the next CC. The arithmetic to put a $18 a share price on an Incyte-like company with the Jakafi franchise and nothing else is routine. So this seems like a very strange time for INCY to be weak.